Six refractory lupus patients treated with rituximab: A case series
Open Access
- 29 March 2007
- journal article
- trainee rounds
- Published by Wiley in Arthritis Care & Research
- Vol. 57 (3) , 538-542
- https://doi.org/10.1002/art.22629
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- B lymphocyte depletion therapy in children with refractory systemic lupus erythematosusArthritis & Rheumatism, 2005
- Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseasesAnnals of the Rheumatic Diseases, 2005
- Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down‐regulation of the T cell costimulatory molecule CD40 ligand: An open‐label trialArthritis & Rheumatism, 2005
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three casesAmerican Journal of Hematology, 2004
- The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosusArthritis & Rheumatism, 2003
- An open study of B lymphocyte depletion in systemic lupus erythematosusArthritis & Rheumatism, 2002
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- Two distinct subsets of patients with systemic lupus erythematosusClinical Immunology and Immunopathology, 1988